Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Raleigh › NPI 1972579837
Hospital

Wakemed

Wakemed was paid $140.71M by Medicaid between Jan 2018 and Dec 2024, across 266 billing codes. Its largest line is 99284, emergency room visit (serious) — 47% of everything it billed.

33Billing provider infoWAKEMED
RALEIGH, NC 27610
33aNPI1972579837assigned 02/28/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$140.71M
24GClaims1,484,819
24DCodes billed266
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018195,121$13.67M
2019186,369$13.55M
2020126,674$10.28M
2021201,268$19.96M
2022229,576$28.97M
2023242,541$26.30M
2024incomplete303,270$27.99M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 47% 183,814 169,605 $65.57M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 21% 166,859 155,699 $29.72M
99282 Emergency department visit for the evaluation and management, low to moderate severity 4.4% 64,003 60,325 $6.22M
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 3.9% 30,056 27,723 $5.43M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 3.7% 13,751 11,901 $5.26M
0240U 2.8% 24,168 22,177 $3.99M
41899 Unlisted procedure, dentoalveolar structures 1.7% 2,146 2,030 $2.38M
G0378 Hospital observation service, per hour 1.4% 10,550 6,556 $2.01M
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 1.2% 47,265 42,535 $1.73M
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.1% 44,005 39,047 $1.54M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 15,850 14,295 $1.37M
71046 Radiologic examination, chest; 2 views <1% 24,954 23,249 $1.35M
254 more codes
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 140,848 $1.25M
80053 Comprehensive metabolic panel <1% 82,201 $905K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 1,413 $787K
96375 Therapeutic injection; each additional sequential IV push <1% 15,010 $768K
90460 Immunization administration through 18 years of age via any route, first or only component <1% 7,064 $578K
96110 Developmental screening, with scoring and documentation, per standardized instrument <1% 7,325 $544K
87631 <1% 5,287 $459K
84703 <1% 48,551 $457K
90461 <1% 5,224 $428K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 18,899 $367K
54161 <1% 431 $353K
99214 Doctor's office visit, returning patient (more involved) <1% 8,842 $332K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 9,316 $287K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 9,318 $283K
70450 Computed tomography, head or brain; without contrast material <1% 1,505 $277K
81001 <1% 64,920 $255K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 8,442 $243K
87086 Culture, bacterial; quantitative colony count, urine <1% 22,426 $237K
83690 <1% 27,918 $216K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 5,352 $210K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 4,877 $209K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,405 $201K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 6,474 $182K
80048 Basic metabolic panel (calcium, ionized) <1% 19,098 $180K
99213 Doctor's office visit, returning patient (routine) <1% 7,552 $178K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 2,756 $165K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,548 $162K
84484 <1% 9,865 $136K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 385 $133K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 810 $132K
J7030 Infusion, normal saline solution , 1000 cc <1% 29,818 $129K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 5,089 $124K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 4,406 $123K
84443 Thyroid stimulating hormone (TSH) <1% 6,590 $111K
87430 <1% 7,069 $111K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 4,792 $110K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 2,563 $96K
80061 Lipid panel <1% 5,194 $94K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 3,744 $92K
81003 <1% 33,665 $92K
85027 <1% 10,782 $84K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 1,493 $80K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 352 $73K
36415 Collection of venous blood by venipuncture <1% 24,641 $69K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 4,297 $65K
86780 <1% 3,907 $64K
76801 <1% 636 $63K
83036 Hemoglobin; glycosylated (A1C) <1% 4,869 $62K
76830 Ultrasound, transvaginal <1% 700 $62K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 139 $56K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 675 $55K
83525 <1% 3,149 $53K
71045 Radiologic examination, chest; single view <1% 1,221 $48K
87081 <1% 6,151 $47K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 467 $44K
86885 <1% 6,099 $42K
J2704 Injection, propofol, 10 mg <1% 4,167 $38K
72125 Computed tomography, cervical spine; without contrast material <1% 199 $38K
83735 <1% 6,097 $37K
90472 Immunization administration, each additional vaccine (list separately) <1% 948 $36K
84439 <1% 3,181 $36K
31720 <1% 768 $34K
76770 <1% 338 $32K
74018 <1% 704 $32K
96127 <1% 2,656 $29K
86900 <1% 6,683 $27K
86901 <1% 6,663 $24K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 353 $22K
J3490 Unclassified drugs <1% 4,547 $21K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 769 $21K
84702 <1% 1,958 $20K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 7,060 $20K
96376 <1% 671 $20K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 485 $19K
83516 <1% 597 $19K
96361 Intravenous infusion, hydration; each additional hour <1% 205 $19K
J7120 Ringers lactate infusion, up to 1000 cc <1% 4,814 $19K
90480 <1% 379 $18K
83880 <1% 689 $17K
73630 <1% 384 $16K
82947 <1% 2,758 $15K
59025 Fetal non-stress test <1% 484 $15K
97161 <1% 291 $14K
77072 <1% 394 $14K
90834 Psychotherapy session, about 45 minutes <1% 243 $13K
0071A <1% 198 $13K
80074 <1% 258 $13K
82607 <1% 824 $13K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 198 $13K
73610 <1% 290 $13K
86140 <1% 1,821 $12K
74019 <1% 202 $12K
83655 <1% 580 $12K
73564 <1% 374 $12K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 204 $11K
90832 Psychotherapy session, about 30 minutes <1% 336 $11K
77067 Screening mammography, bilateral, including computer-aided detection <1% 217 $11K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 38 $10K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 854 $10K
76642 <1% 167 $10K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 263 $9K
87210 <1% 1,873 $8K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 344 $8K
80076 <1% 1,012 $8K
87040 <1% 553 $8K
87077 <1% 948 $8K
87150 <1% 210 $8K
82784 <1% 624 $8K
90791 Psychiatric diagnostic evaluation <1% 54 $7K
J2060 Injection, lorazepam, 2 mg <1% 2,193 $7K
0081A <1% 105 $7K
85610 <1% 1,824 $7K
86762 <1% 335 $6K
87186 <1% 675 $6K
86787 <1% 351 $6K
M0247 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring <1% 23 $6K
70486 <1% 31 $6K
73130 <1% 156 $5K
85651 <1% 1,283 $5K
73030 <1% 130 $5K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 6,634 $5K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 4,967 $5K
87340 <1% 408 $5K
99201 <1% 323 $4K
97802 <1% 204 $4K
82728 <1% 296 $4K
86803 <1% 242 $4K
96380 <1% 123 $4K
84450 <1% 1,507 $4K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 161 $4K
97803 <1% 261 $4K
D1206 Topical application of fluoride varnish <1% 292 $4K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 123 $4K
73110 <1% 113 $4K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 14 $4K
86777 <1% 188 $3K
94664 <1% 238 $3K
96113 <1% 28 $3K
0124A <1% 45 $3K
J2550 Injection, promethazine hcl, up to 50 mg <1% 324 $3K
82570 <1% 518 $3K
85379 <1% 324 $3K
82746 <1% 204 $3K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 4,281 $3K
85014 <1% 639 $3K
85018 <1% 639 $3K
85652 <1% 558 $2K
83020 <1% 143 $2K
96112 <1% 28 $2K
86592 <1% 528 $2K
82565 <1% 460 $2K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,414 $2K
A0427 Emergency ambulance ride, advanced life support <1% 18 $2K
0053A <1% 29 $2K
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,185 $2K
J1630 Injection, haloperidol, up to 5 mg <1% 1,650 $2K
72110 <1% 28 $2K
82105 <1% 88 $2K
12011 <1% 32 $2K
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 1,400 $2K
86255 <1% 119 $2K
86038 <1% 154 $2K
90677 <1% 2,160 $2K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 768 $2K
0154A <1% 25 $2K
83021 <1% 73 $2K
10060 <1% 30 $2K
J7999 Compounded drug, not otherwise classified <1% 731 $1K
90847 Family psychotherapy with the patient present, 50 minutes <1% 32 $1K
90715 <1% 81 $1K
84460 <1% 1,522 $1K
85730 <1% 300 $1K
0001A <1% 21 $1K
29125 <1% 30 $1K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 33 $1K
96160 <1% 159 $1K
82950 <1% 242 $1K
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg <1% 174 $1K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 23 $949.65
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 1,165 $945.39
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 922 $936.07
90837 Psychotherapy session, about an hour <1% 18 $915.30
99203 Doctor's office visit, new patient (routine) <1% 42 $874.35
82247 <1% 154 $869.46
82164 <1% 82 $852.64
83550 <1% 87 $844.84
0173A <1% 12 $835.60
J7050 Infusion, normal saline solution, 250 cc <1% 426 $832.98
83540 <1% 115 $828.87
90656 <1% 1,279 $828.02
84550 <1% 524 $805.43
J1050 Injection, medroxyprogesterone acetate, 1 mg <1% 12 $800.84
84165 <1% 94 $774.41
0082A <1% 13 $739.94
73080 <1% 17 $731.50
83605 <1% 94 $715.51
J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg <1% 1,277 $696.67
73140 <1% 24 $664.51
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 507 $664.00
J7510 Prednisolone oral, per 5 mg <1% 296 $663.00
80164 <1% 47 $638.76
96381 <1% 16 $580.00
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 318 $489.47
85660 <1% 73 $475.00
82248 <1% 168 $457.58
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 13 $440.80
84436 <1% 102 $434.84
G0109 Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes <1% 26 $434.32
83520 <1% 24 $403.25
84132 <1% 106 $389.94
82043 <1% 55 $368.23
86431 <1% 89 $368.16
87147 <1% 57 $367.65
90686 <1% 2,747 $367.28
86308 <1% 69 $354.75
90381 <1% 89 $341.66
83615 <1% 171 $331.77
J0290 Injection, ampicillin sodium, 500 mg <1% 50 $328.58
90647 <1% 2,418 $311.52
J0171 Injection, adrenalin, epinephrine, 0.1 mg <1% 13 $310.23
82550 <1% 49 $309.94
83002 <1% 13 $300.04
83001 <1% 13 $287.92
84153 <1% 28 $256.20
90723 <1% 2,669 $246.33
S0028 Injection, famotidine, 20 mg <1% 317 $236.83
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 550 $221.10
81025 <1% 25 $220.31
90681 <1% 841 $183.04
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 59 $170.42
90633 <1% 572 $160.30
90670 <1% 1,130 $145.99
J0780 Injection, prochlorperazine, up to 10 mg <1% 14 $109.20
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 143 $105.04
80178 <1% 12 $101.45
84100 <1% 30 $98.13
J0690 Injection, cefazolin sodium, 500 mg <1% 52 $72.64
85045 <1% 15 $64.87
86364 <1% 13 $55.08
C9399 Unclassified drugs or biologicals <1% 79 $39.99
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 18 $38.90
84155 <1% 12 $4.57
90710 0% 53 $0.00
G1010 Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program 0% 94 $0.00
90700 0% 58 $0.00
91321 0% 215 $0.00
90707 0% 89 $0.00
90680 0% 1,153 $0.00
90619 0% 46 $0.00
90716 0% 86 $0.00
90620 0% 37 $0.00
90651 0% 113 $0.00
90696 0% 39 $0.00
91315 0% 13 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSESSOMS, STEPHANIE (EXECUTIVE VP, FINANCE & CFO)
Parent organizationWAKEMED
Same official

Other billing entities under SESSOMS, STEPHANIE

Full network →
ProviderLocationPaid
WakemedCary, NC$4.12M
WakemedRaleigh, NC$14K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.